» Articles » PMID: 32320003

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Abstract

Importance: There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).

Objective: To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system.

Design, Setting, And Participants: Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates.

Exposures: Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission.

Main Outcomes And Measures: Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected.

Results: A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1).

Conclusions And Relevance: This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.

Citing Articles

Development and validation of a nomogram to assess the occurrence of liver dysfunction in patients with COVID-19 pneumonia in the ICU.

Wang Z, Zhao L, Xie K BMC Infect Dis. 2025; 25(1):332.

PMID: 40065225 PMC: 11892215. DOI: 10.1186/s12879-025-10684-1.


COVID-19 among kidney transplant recipients: evaluating risk factors during the initial phase of the pandemic.

Nowak A, Caldinelli A, Segelmark M, Rydell H, Artborg A, Bellocco R Clin Kidney J. 2025; 18(3):sfaf030.

PMID: 40052164 PMC: 11883224. DOI: 10.1093/ckj/sfaf030.


Identifying and Validating Prognostic Hyper-Inflammatory and Hypo-Inflammatory COVID-19 Clinical Phenotypes Using Machine Learning Methods.

Ji X, Guo Y, Tang L, Gao C J Inflamm Res. 2025; 18:3009-3024.

PMID: 40034687 PMC: 11874972. DOI: 10.2147/JIR.S504028.


The blood urea nitrogen-to-creatinine ratio is associated with acute kidney injury among COVID-19 patients.

Zhong X, Wang X, Feng X, Yu H, Chen Z, Chen X Ren Fail. 2025; 47(1):2442049.

PMID: 40033758 PMC: 11881656. DOI: 10.1080/0886022X.2024.2442049.


Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.

Bi C, He J, Yuan Y, Che S, Cui T, Ning L J Glob Health. 2025; 15:04056.

PMID: 40019163 PMC: 11869518. DOI: 10.7189/jogh.15.04056.


References
1.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

2.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M . Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; 323(16):1612-1614. PMC: 7082763. DOI: 10.1001/jama.2020.4326. View

3.
Sommerstein R, Kochen M, Messerli F, Grani C . Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?. J Am Heart Assoc. 2020; 9(7):e016509. PMC: 7428596. DOI: 10.1161/JAHA.120.016509. View

4.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

5.
Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View